Altai Protocol Library

1023 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Reference: Cemiplimab for first-line treatment of advanced non-small-cell lung cancer (PD-L1 >=50%)

New Reference: Cemiplimab for first-line treatment of advanced non-small-cell lung cancer (PD-L1 >=50%)
Study:
  • Phase III, open-label (EMPOWER-Lung 1)
  • Advanced NSCLC with PD-L1 >=50%. Never-smokers excluded
  • Cemiplimab 350 q21 (n=283) vs. platinum doublet (n=280). Crossover from chemo to cemiplimab allowed
Efficacy:
  • ORR: 39% vs. 20% (OR: 2.53 [1.74-3.69])
  • Median PFS: 8.2 mos [6.1-8.8 mos] vs. 5.7 mos [4.5-6.2 mos] (HR: 0.54 [0.43-0.68])
  • Median OS: NR [17.9 mos – NE] vs. 14.2 mos [11.2-17.5 mos] (HR: 0.57 [0.42-0.77])
  • Among pts with PD-L1 >=90%: Median PFS: 15.3 mos (n=98) vs. 5.9 mos (n=94)
Safety:
  • Grade >=3 AEs: Thrombocytopenia (0% vs. 8%), neutropenia (1% vs. 10%), immune-mediated hepatitis (1% vs. 0%)

Lancet 2021;397:592.

Sezer A, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

https://doi.org/10.1016/S0140-6736(21)00228-2

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More